U.S. PHARMACOPEIA

Search USP29  
Milrinone
Click to View Image
C12H9N3O 211.22
[3,4¢-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo-.
1,6-Dihydro-2-methyl-6-oxo[3,4¢-bipyridine]-5-carbonitrile [78415-72-2].
» Milrinone contains not less than 98.5 percent and not more than 101.5 percent of C12H9N3O, calculated on the anhydrous basis.
Caution—Milrinone is a cardiotonic agent.
Packaging and storage— Preserve in tight containers, and store at controlled room temperature.
Identification—
B: The retention time of the major peak in the chromatogram of the Test solution corresponds to that in the chromatogram of the Standard solution, as obtained in the test for Chromatographic purity.
Water, Method I 921: not more than 2.0%.
Residue on ignition 281: not more than 0.2%.
Chromatographic purity—
pH 7.5 Phosphate buffer— Dissolve 2.7 g of dibasic potassium phosphate in 800 mL of water, add 2.4 mL of triethylamine, adjust with phosphoric acid to a pH of about 7.5, and mix.
Mobile phase— Prepare a filtered and degassed mixture of pH 7.5 Phosphate buffer and acetonitrile (80:20). Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard stock solution— Dissolve an accurately weighed quantity of USP Milrinone RS in Mobile phase to obtain a solution having a known concentration of about 2 mg per mL, heat in a water bath at approximately 80, and/or sonicate, if necessary.
Standard solution— Dilute an appropriate volume of Standard stock solution quantitatively, and stepwise if necessary, with Mobile phase to obtain a solution having a known concentration of 0.006 mg per mL.
System suitability solution— Dissolve an accurately weighed quantity of USP Milrinone Related Compound A RS in Mobile phase to obtain a solution having a known concentration of about 0.2 mg per mL. Heat in a water bath at approximately 80, and/or sonicate, if necessary, to dissolve. Transfer 10.0 mL of this solution and 1.0 mL of the Standard stock solution to a 100-mL volumetric flask, dilute with Mobile phase to volume, and mix.
Test solution— Transfer about 100 mg of Milrinone, accurately weighed, to a 50-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix. Heat in a water bath at approximately 80, if necessary.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 220-nm detector and a 4.6-mm × 25-cm column that contains packing L7. The flow rate is about 1 mL per minute. Chromatograph the System suitability solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.6 for milrinone related compound A and 1.0 for milrinone; the resolution, R, between milrinone related compound A and milrinone is not less than 4.0; and the relative standard deviation for replicate injections of milrinone is not more than 5.0%.
Procedure— Separately inject equal volumes (about 20 µL) of the Test solution and the Standard solution into the chromatograph, record the chromatograms, and measure all the peak responses. Calculate the percentage of each impurity in the portion of Milrinone taken by the formula:
5000(C/W)(ri / rS),
in which C is the concentration, in mg per mL, of USP Milrinone RS in the Standard solution; W is the weight, in mg, of milrinone taken to prepare the Test solution; ri is the peak response for each impurity obtained from the Test solution; and rS is the peak response obtained from the Standard solution: not more than 0.3% of any individual impurity is found; and not more than 1.0% of total impurities is found.
Organic volatile impurities, Method V 467: meets the requirements.
Solvent— Use dimethyl sulfoxide.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay— Transfer about 200 mg of Milrinone, accurately weighed, to a 100-mL beaker, and dissolve by stirring in 50 mL of glacial acetic acid. Titrate with 0.1 N perchloric acid VS, determining the endpoint potentiometrically. Perform a blank determination, and make any necessary correction. Each mL of 0.1 N perchloric acid VS is equivalent to 21.12 mg of C12H9N3O.
Auxiliary Information— Staff Liaison : Andrzej Wilk, Ph.D., Senior Scientific Associate
Expert Committee : (MDCV05) Monograph Development-Cardiovascular
USP29–NF24 Page 1437
Pharmacopeial Forum : Volume No. 29(5) Page 1538
Phone Number : 1-301-816-8305